KRAS Alleles: The Devil Is in the Detail

Cited by (376)

Items 101–200 of 376

1. KRAS-targeted therapies in colorectal cancer: a systematic analysis of mutations, inhibitors, and clinical trials
   Maria Navarro-Jiménez, Beatríz González, Núria Mulet-Margalef, Cinta Hierro, Sergio Alonso · 2025 · npj Precision Oncology
2. An integrative pharmacogenomics analysis identifies therapeutic targets in KRAS-mutant lung cancer
   Haiyun Wang, Qi Lv, Yue Xu, Zhaoqing Cai, Jie Zheng, Xiaojie Cheng, Yao Dai, Pasi Antero Janne, Chiara Ambrogio, Jens Köhler · 2019 · EBioMedicine
3. Targeting the KRAS oncogene: Synthesis, physicochemical and biological evaluation of novel G-Quadruplex DNA binders
   Federica D’Aria, Vincenzo Maria D’Amore, Francesco Saverio Di Leva, Jussara Amato, Marco Caterino, Pasquale Russomanno, Silvia Salerno, Elisabetta Barresi, Marinella De Leo, Anna María Marini et al. · 2020 · European Journal of Pharmaceutical Sciences
4. Targeting KRAS in Lung Cancer Beyond KRAS G12C Inhibitors: The Immune Regulatory Role of KRAS and Novel Therapeutic Strategies
   Marc Cucurull, Lucía Notario, Montse Sánchez‐Céspedes, Cinta Hierro, Anna Estival, Enric Carcereny, Maria Saigí · 2022 · Frontiers in Oncology
5. Recurrent driver mutations in benign tumors
   Carolina Cavaliéri Gomes · 2022 · Mutation Research/Reviews in Mutation Research
6. Target-Based Small Molecule Drug Discovery for Colorectal Cancer: A Review of Molecular Pathways and In Silico Studies
   Said Moshawih, Lim Ai Fern, Chrismawan Ardianto, Khang Wen Goh, Nurolaini Kifli, Hui Poh Goh, Qais Jarrar, Long Chiau Ming · 2022 · Biomolecules
7. Recent progress in targeting KRAS mutant cancers with covalent G12C-specific inhibitors
   Lala S. Rathod, Pratap S. Dabhade, Santosh N. Mokale · 2023 · Drug Discovery Today
8. Interplay between K-RAS and miRNAs
   Bing Shui, Gaspare La Rocca, Andrea Ventura, Kevin M. Haigis · 2022 · Trends in cancer
9. Free Energy Profiles Relating With Conformational Transition of the Switch Domains Induced by G12 Mutations in GTP-Bound KRAS
   Jianzhong Chen, Shaolong Zhang, Qingkai Zeng, Wei Wang, Qinggang Zhang, Xinguo Liu · 2022 · Frontiers in Molecular Biosciences
10. Structural basis of the atypical activation mechanism of KRASV14I
    Asim K. Bera, Jia Lu, Thomas E. Wales, Sudershan Reddy Gondi, Deepak Gurbani, Andrew Nelson, John R. Engen, Kenneth D. Westover · 2019 · Journal of Biological Chemistry
11. Computationally Empowered Workflow Identifies Novel Covalent Allosteric Binders for KRASG12C
    Jérémie Mortier, Anders Friberg, Volker Badock, Dieter Moosmayer, Jens Schroeder, Patrick Steigemann, Franziska Siegel, Stefan Gradl, Marcus Bauser, Roman Christian Hillig et al. · 2020 · ChemMedChem
12. Capturing the primordial Kras mutation initiating urethane carcinogenesis
    Siqi Li, David M. MacAlpine, Christopher M. Counter · 2020 · Nature Communications
13. Mechanism of activation and the rewired network: New drug design concepts
    Ruth Nussinov, Mingzhen Zhang, Ryan Maloney, Chung‐Jung Tsai, Bengi Ruken Yavuz, Nurcan Tunçbağ, Hyunbum Jang · 2021 · Medicinal Research Reviews
14. KRAS Hijacks the miRNA Regulatory Pathway in Cancer
    Angelina S. Bortoletto, Ronald J. Parchem · 2023 · Cancer Research
15. The ER-mitochondria Ca2+ signaling in cancer progression: Fueling the monster
    Galdo Bustos, Ulises Ahumada-Castro, Eduardo Silva-Pavez, Andrea Puebla, Alenka Lovy, César Cárdenas · 2021 · International review of cytology
16. Thermal Shift Assay for Small GTPase Stability Screening: Evaluation and Suitability
    Kari Kopra, Salla Valtonen, Randa Mahran, Jonas N. Kapp, Nazia Hassan, William Gillette, Bryce Dennis, Lianbo Li, Kenneth D. Westover, Andreas Plückthun et al. · 2022 · International Journal of Molecular Sciences
17. Targeting mutant KRAS
    Daniel A. Erlanson, Kevin R. Webster · 2021 · Current Opinion in Chemical Biology
18. Dysregulated KRAS gene-signaling axis and abnormal chromatin remodeling drive therapeutic resistance in heterogeneous-sized circulating tumor cells in gastric cancer patients
    Yang Chen, Yanyan Li, Changsong Qi, Cheng Zhang, Dan Liu, Youping Deng, Yuanyuan Fu, Vedbar S. Khadka, Daisy Dandan Wang, Shanyang Tan et al. · 2021 · Cancer Letters
19. Oncogenic KRAS-Induced Feedback Inflammatory Signaling in Pancreatic Cancer: An Overview and New Therapeutic Opportunities
    Sapana Bansod, Paarth B. Dodhiawala, Kian‐Huat Lim · 2021 · Cancers
20. Mutations matter: An observational study of the prognostic and predictive value of KRAS mutations in metastatic colorectal cancer
    Daniele Lavacchi, Sara Fancelli, Giandomenico Roviello, Francesca Castiglione, Enrico Caliman, Gemma Rossi, Jacopo Venturini, Elisa Pellegrini, Marco Brugia, Agnese Vannini et al. · 2022 · Frontiers in Oncology
21. Driver Mutations in Pancreatic Cancer and Opportunities for Targeted Therapy
    Olamide Tosin Olaoba, Temitope Isaac Adelusi, Ming Jun Yang, Tessa Maidens, Eric T. Kimchi, Kevin F. Staveley-O’Carroll, Guangfu Li · 2024 · Cancers
22. Dynamically encoded reactivity of Ras enzymes: opening new frontiers for drug discovery
    Gyula Pálfy, Dóra K. Menyhárd, András Perczel · 2020 · Cancer and Metastasis Reviews
23. Cytotoxicity of combinations of the pan-KRAS SOS1 inhibitor BAY-293 against pancreatic cancer cell lines
    Plangger, Adelina, Rath, Barbara, Stickler, Sandra, Hochmair, Maximilian, Lang, Clemens, Weigl, Lukas, Funovics, Martin, Hamilton, Gerhard · 2022 · Discover Oncology
24. Abrogation of ARF6 in promoting erastin-induced ferroptosis and mitigating capecitabine resistance in gastric cancer cells
    Donghua Geng, Huiying Wu · 2022 · Journal of Gastrointestinal Oncology
25. KrasP34R and KrasT58I mutations induce distinct RASopathy phenotypes in mice
    Jasmine C. Y. Wong, Pedro Antonio Pérez-Mancera, Tannie Q. Huang, Jangkyung Kim, Joaquím Grego‐Bessa, Maria del pilar Alzamora, Scott C. Kogan, Amnon Sharir, Susan H. Keefe, Carolina E. Morales et al. · 2020 · JCI Insight
26. KRAS as a Key Oncogene in the Clinical Precision Diagnosis and Treatment of Pancreatic Cancer
    Manxiong Dai, Shaofeng Chen, Xiong Teng, Kang Chen, Wei Cheng · 2022 · Journal of Cancer
27. KRAS A146 Mutations Are Associated With Distinct Clinical Behavior in Patients With Colorectal Liver Metastases
    Iris van ’t Erve, Nina J. Wesdorp, Jamie E. Medina, Leonardo Ferreira, Alessandro Leal, Joost Huiskens, Karen Bolhuis, Jan‐Hein T. M. van Waesberghe, Rutger‐Jan Swijnenburg, Daan A. van den Broek et al. · 2021 · JCO Precision Oncology
28. Lung cancer molecular mutations and abnormal glycosylation as biomarkers for early diagnosis
    Shuang Yang, Jun Xia, Zeren Yang, Mingming Xu, Shuwei Li · 2021 · Cancer Treatment and Research Communications
29. KRAS allelic imbalance drives tumour initiation yet suppresses metastasis in colorectal cancer in vivo
    Arafath Kaja Najumudeen, Sigrid K. Fey, Laura M. Millett, Catriona A. Ford, Kathryn L. Gilroy, Nuray Gündüz, Rachel A. Ridgway, Eve Anderson, Douglas Strathdee, William Andrew Clark et al. · 2024 · Nature Communications
30. KRAS mutations in brown tumor of the jaws in hyperparathyroidism
    Letícia Martins Guimarães, Isadora Pereira Gomes, Thaís dos Santos Fontes Pereira, Bruno Augusto Benevenuto de Andrade, Mário José Romañach, Júlio César Tanos de Lacerda, Hélder Antônio Rebelo Pontes, Peter A. Brennan, Siavash Rahimi, Román Carlos et al. · 2020 · Journal of Oral Pathology and Medicine
31. A New Strategy to Control and Eradicate “Undruggable” Oncogenic K-RAS-Driven Pancreatic Cancer: Molecular Insights and Core Principles Learned from Developmental and Evolutionary Biology
    Robert E. Van Sciver, Michael Lee, Caroline Guat Lay Lee, Alex Lafever, Elizaveta A. Svyatova, Kevin Kanda, Amber L. Collier, Lauren L. Siewertsz van Reesema, Angela M. Tang-Tan, Vasilena P. Zheleva et al. · 2018 · Cancers
32. KRAS mutational status impacts pathologic response to pre-hepatectomy chemotherapy: a study from the International Genetic Consortium for Liver Metastases
    Georgios Antonios Margonis, Neda Amini, Nikolaos Andreatos, Kazunari Sasaki, Jack McVey, Muhammad Bilal Mirza, Samuel B. Warner, Stefan Buettner, Carlotta Barbon, Jane Wang et al. · 2019 · HPB
33. Meta-Analysis of Circulating Cell-Free DNA’s Role in the Prognosis of Pancreatic Cancer
    Jelena S. Milin-Lazovic, Petar Madzarevic, Nina Rajović, Vladimir R. Djordjevic, Nikola Milic, Sonja Pavlović, Nevena Veljković, Natasa M Milic, Dejan V. Radenkovic · 2021 · Cancers
34. Genetic Profile of Adenomatoid Odontogenic Tumor and Ameloblastoma. A Systematic Review
    Constanza Celia Nieto Marín, Sven Eric Niklander, Rene Flores · 2021 · Frontiers in Oral Health
35. Regulation of GTPase function by autophosphorylation
    Christian William Johnson, Hyuk‐Soo Seo, Elizabeth M. Terrell, Moon-Hee Yang, Fenneke KleinJan, Teklab Gebregiworgis, Geneviève M. C. Gasmi-Seabrook, Ezekiel A. Geffken, Jimit Lakhani, Kijun Song et al. · 2022 · Molecular Cell
36. The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models
    Katie E. Hebron, Xiaolin Wan, Jacob S. Roth, David J. Liewehr, Nancy E. Sealover, William J.E. Frye, Angela Kim, Stacey Stauffer, Olivia L. Perkins, Wenyue Sun et al. · 2022 · Clinical Cancer Research
37. Hyperactive KRAS/MAPK signaling disrupts normal lymphatic vessel architecture and function
    Lorenzo M. Fernandes, Jeffrey D. Tresemer, Jing Zhang, Jonathan J. Rios, Joshua Paul Scallan, Michael T. Dellinger · 2023 · Frontiers in Cell and Developmental Biology
38. High expression of LAMA3/AC245041.2 gene pair associated with KRAS mutation and poor survival in pancreatic adenocarcinoma: a comprehensive TCGA analysis
    Chengming Tian, Xiyao Li, Chunlin Ge · 2021 · Molecular Medicine
39. Safety assessment of KRAS (G12C) inhibitors based on the FDA Adverse Event Reporting System (FAERS) database: A real-world pharmacovigilance study
    Maohua Chen, Yaping Huang, Shaojun Jiang, Chengjie Ke · 2024 · Lung Cancer
40. Phenotypic heterogeneity and tumor immune microenvironment directed therapeutic strategies in pancreatic ductal adenocarcinoma
    Remya P. G. Ramesh, Hadida Yasmin, Pretty Ponnachan, Basel K. al-Ramadi, Uday Kishore, Ann Mary Joseph · 2025 · Frontiers in Immunology
41. Treatment of KRAS-Mutated Pancreatic Cancer: New Hope for the Patients?
    Kamila Krupa, Marta Magdalena Fudalej, Emilia Włoszek, Hanna Miski, Anna Maria Badowska-Kozakiewicz, Dominika Mękal, Michał Piotr Budzik, Aleksandra Izabela Czerw, Andrzej Deptała · 2025 · Cancers
42. KSR1- and ERK-dependent translational regulation of the epithelial-to-mesenchymal transition
    Chaitra Rao, Danielle E. Frodyma, Siddesh Southekal, Robert A. Svoboda, Adrian R. Black, Chittibabu Guda, Tomohiro Mizutani, Hans C. Clevers, Keith R. Johnson, Kurt W. Fisher et al. · 2021 · eLife
43. Colorectal cancer murine models: Initiation to metastasis
    Ramesh Pothuraju, Imran Khan, Maneesh Jain, Michael Bouvet, Mokenge Peter Malafa, Hemant K. Roy, Sushil Kumar K, Surinder K. Batra · 2024 · Cancer Letters
44. Investigating underlying molecular mechanisms, signaling pathways, emerging therapeutic approaches in pancreatic cancer
    Mohd Mustafa, Kashif Abbas, Mudassir Alam, Safia Habib, Zulfareen, Gulam Mustafa Hasan, Sidra Islam, Anas Shamsi, Md. Imtaiyaz Hassan · 2024 · Frontiers in Oncology
45. Mutational analysis of uterine cervical cancer that survived multiple rounds of radiotherapy
    Endang Nuryadi, Yasushi Sasaki, Yoshihiko Hagiwara, Tiara Bunga Mayang Permata, Hiro Sato, Shuichiro Komatsu, Yuya Yoshimoto, Kazutoshi Murata, Ken Ando, Nobuteru Kubo et al. · 2018 · Oncotarget
46. Loss of wild type KRAS in KRAS lung adenocarcinoma is associated with cancer mortality and confers sensitivity to FASN inhibitors
    Yan Liu, Galen F. Gao, John Dorrance Minna, Noelle Sevilir Williams, Kenneth D. Westover · 2021 · Lung Cancer
47. Long non-coding RNA TP73-AS1 promotes pancreatic cancer growth and metastasis through miRNA-128-3p/GOLM1 axis
    Bin Wang, Xing Sun, Kejian Huang, Li-Sheng Zhou, Zhengjun Qiu · 2021 · World Journal of Gastroenterology
48. Cobimetinib Plus Gemcitabine: An Active Combination in KRAS G12R-Mutated Pancreatic Ductal Adenocarcinoma Patients in Previously Treated and Failed Multiple Chemotherapies
    Bach Ardalan, Jose Ignacio Azqueta, Danny Sleeman · 2021 · Journal of Pancreatic Cancer
49. Co-treatment of betulin and gefitinib is effective against EGFR wild-type/KRAS-mutant non-small cell lung cancer by inducing ferroptosis
    Wei-Ya Yan, Jian Cai, Jiang-Nan Wang, Yong-Sheng Gong, Xue-Bing Ding · 2022 · Neoplasma
50. Effects of MIR143 on rat sarcoma signaling networks in solid tumors: A brief overview
    Yoshihisa Tokumaru, Kazuaki Takabe, Kazuhiro Yoshida, Yukihiro Akao · 2020 · Cancer Science
51. Targeting the ERK mitogen-activated protein kinase cascade for the treatment of KRAS-mutant pancreatic cancer
    J. Nathaniel Diehl, Priya S. Hibshman, Irem Ozkan‐Dagliyan, Craig M. Goodwin, Sarah V. Howard, Adrienne D. Cox, Channing J. Der · 2022 · Advances in cancer research
52. Role of ferroptosis in gastrointestinal tumors: From mechanisms to therapies
    Chenli Si, Xiang Zhou, Jie Deng, Shijie Ye, Lingming Kong, Baofu Zhang, Weiming Wang · 2022 · Cell Biology International
53. Targeting KRASG12V mutations with HLA class II-restricted TCR for the immunotherapy in solid tumors
    Qi Ai, Fanlu Li, Siyi Zou, Zehui Zhang, Yangbing Jin, Lingxi Jiang, Hao Chen, Xiaxing Deng, Chenghong Peng, Nan Mou et al. · 2023 · Frontiers in Immunology
54. Mutation-Specific and Common Phosphotyrosine Signatures of KRAS G12D and G13D Alleles
    Raiha Tahir, Santosh Renuse, Savita Udainiya, Anil Kumar Madugundu, Jevon A. Cutler, Raja Sekhar Nirujogi, Chan Hyun Na, Yaoyu Xu, Xinyan Wu, Akhilesh Pandey · 2020 · Journal of Proteome Research
55. Targeting KRAS in pancreatic cancer: Emerging therapeutic strategies
    Sajid Ullah Khan, Vivekananda Budamagunta, Daohong Zhou · 2023 · Advances in cancer research
56. Oncogenic K-Ras suppresses global miRNA function
    Bing Shui, Tyler S. Beyett, Zhengyi Chen, Xiaoyi Li, Gaspare La Rocca, William Gazlay, Michael J. Eck, Ken S. Lau, Andrea Ventura, Kevin M. Haigis · 2023 · Molecular Cell
57. Proteomics reveals a therapeutic vulnerability via the combined blockade of APE1 and autophagy in lung cancer A549 cells
    Shuting Pan, Ji Zhou, Fang Yang, Shu‐Feng Zhou, Tao Ren · 2020 · BMC Cancer
58. Wild-Type KRAS Allele Effects on Druggable Targets in KRAS Mutant Lung Adenocarcinomas
    Elisa Baldelli, Emna El Gazzah, John Conor Moran, Kimberley Alex Hodge, Zarko Manojlovic, Rania Bassiouni, John David Carpten, Vienna Ludovini, Sara Baglivo, Lucio Crinò et al. · 2021 · Genes
59. Colorectal Cancer Modeling with Organoids: Discriminating between Oncogenic RAS and BRAF Variants
    Jasmin B. Post, Jeanine M.L. Roodhart, Hugo J.G. Snippert · 2020 · Trends in cancer
60. A novel platform for mutation detection in colorectal cancer using a PNA-LNA molecular switch
    Md. Sajedul Islam, Sharmin Aktar, Neda Moetamedirad, Nan Xie, Cu‐Tai Lu, Vinod Gopalan, Alfred King-yin Lam, Muhammad J. A. Shiddiky · 2024 · Biosensors and Bioelectronics
61. Pharmacophoric analogs of sotorasib-entrapped KRAS G12C in its inactive GDP-bound conformation: covalent docking and molecular dynamics investigations
    Abdul-Quddus Kehinde Oyedele, Abdeen Tunde Ogunlana, Ibrahim Damilare Boyenle, Najahtulahi Opeyemi Ibrahim, Ibrahim Olajide Gbadebo, Nurudeen Owolabi, Mojeed Ayoola Ashiru, Ann Christopher Francis, Olajumoke Eyinade, Temitope Isaac Adelusi · 2022 · Molecular Diversity
62. Allosteric Regulation of Switch-II Domain Controls KRAS Oncogenicity
    Moon Hee Yang, Timothy H. Tran, Bethany Hunt, Rebecca Agnor, Christian William Johnson, Bing Shui, Timothy J. Waybright, Jonathan Andrew Nowak, Andrew G. Stephen, Dhirendra K. Simanshu et al. · 2023 · Cancer Research
63. KRAS mutations in implant‐associated peripheral giant cell granuloma
    Roberta Rayra Martins‐Chaves, Letícia Martins Guimarães, Thaís dos Santos Fontes Pereira, Núbia Braga Pereira, Bruno Ramos Chrcanovic, Felipe Paiva Fonseca, Irene Lafuente‐Ibáñez de Mendoza, José Manuel Aguirre‐Urizar, Carolina Cavaliéri Gomes, Ricardo Santiago Gomez · 2019 · Oral Diseases
64. Clinical implication of oncogenic somatic mutations in early-stage cervical cancer with radical hysterectomy
    Takafumi Watanabe, Hideaki Nanamiya, Manabu Kojima, Shinji Nomura, Shigenori Furukawa, Shu Soeda, Daisuke Tanaka, Takao Isogai, Jun‐ichi Imai, Shinya Watanabe et al. · 2020 · Scientific Reports
65. From precursor to cancer: decoding the intrinsic and extrinsic pathways of pancreatic intraepithelial neoplasia progression
    Sarah Graham, Mariia Dmitrieva, Debora Barbosa Vendramini Costa, Ralph Francescone, María Aurora Martínez Trujillo, Edna Cukierman, Laura DeLong Wood · 2024 · Carcinogenesis
66. Prognostic value of KRAS subtype in patients with PDAC undergoing radical resection
    Manxiong Dai, Raja Jahanzaib, Yan Liao, Fengxuan Yao, Jia Li, Xiong Teng, Kang Chen, Wei Cheng · 2022 · Frontiers in Oncology
67. The Importance of Mg 2+ ‐Free State in Nucleotide Exchange of Oncogenic K‐Ras Mutants
    Gyula Pálfy, Dóra K. Menyhárd, Hanna Ákontz‐Kiss, István Vida, Gyula Batta, Orsolya Tőke, András Perczel · 2022 · Chemistry - A European Journal
68. Impact and clinical usefulness of genetic data in the surgical management of colorectal cancer liver metastasis: a narrative review
    Georgios Antonios Margonis, Martin Ernst Kreis, Jane Wang, Carsten Kamphues, Christopher Lee Wolfgang, Matthew John Weiss · 2020 · HepatoBiliary Surgery and Nutrition
69. Single cell mutational profiling delineates clonal trajectories in myeloid malignancies
    Linde A. Miles, Robert L. Bowman, Tiffany R. Merlinsky, Isabelle Sara Csete, Aik Teong Ooi, Robert Durruthy-Durruthy, Michael Bowman, Christopher A. Famulare, Minal A. Patel, Pedro Méndez et al. · 2020 · bioRxiv (Cold Spring Harbor Laboratory)
70. Novel strategy for oncogenic alteration-induced lipid metabolism reprogramming in pancreatic cancer
    Duancheng Guo, Long‐Yun Ye, Weiding Wu, Xianjun Yu, Kaizhou Jin · 2023 · Acta Biochimica et Biophysica Sinica
71. Decoding KRAS dynamics: Exploring the impact of mutations and inhibitor binding
    Divya Pandey, Kuldeep Kumar Roy · 2024 · Archives of Biochemistry and Biophysics
72. In silico comparative analysis of KRAS mutations at codons 12 and 13: Structural modifications of P-Loop, switch I&II regions preventing GTP hydrolysis
    Michael Gerber, Sanjay Goel, Radhashree Maitra · 2021 · Computers in Biology and Medicine
73. KRAS Mutation: Characterization and Its Impact on Survival Outcome of Patients with Metastatic Colorectal Cancer
    Datul Damit, Ravi Sekhar Patnaik, Liling Chaw, Shir Kiong Lu, Pemasiri Upali Telisinghe, Zen Huat Lu, Kenneth Yuh Yen Kok, Long Chiau Ming, Ya Chee Lim · 2022 · Frontiers in Bioscience-Landmark
74. Genetic Signature of Human Pancreatic Cancer and Personalized Targeting
    Stephan J. Reshkin, Rosa Angela Cardone, Tomas Koltai · 2024 · Cells
75. KRAS gene polymorphisms are associated with the risk of glioma: a two-center case-control study
    Qian Guan, Yuan Li, Ao Lin, Huiran Lin, Xiaokai Huang, Jichen Ruan, Zhenjian Zhuo · 2021 · Translational Pediatrics
76. A single-cell atlas of normal and KRASG12D-malformed lymphatic vessels
    Lorenzo M. Fernandes, Danielle Griswold-Wheeler, Jeffrey D. Tresemer, Angelica Vallejo, Neda Vishlaghi, Benjamin Lévi, Abigail Shapiro, Joshua Paul Scallan, Michael T. Dellinger · 2025 · JCI Insight
77. Cascade‐Targeted Nanoparticles for Enhanced Gemcitabine Delivery and Adenosine Metabolism Modulation to Overcome Treatment Resistance in Pancreatic Cancer
    Hongrui Fan, Hongyi Chen, Haolin Song, Chufeng Li, Yu Wang, Zhenhao Zhao, Qin Guo, Xuwen Li, Mingxuan Liu, Tao Sun et al. · 2025 · Advanced Science
78. Reprogramming Immunosuppressive Niches and the Cancer Immunity Cycle in Pancreatic Cancer with Neoantigen mRNA Plus Immune Adjuvant Nanocarrier Strategies
    André E. Nel, Lijia Luo, Yu‐Pei Liao, Xiang Wang · 2025 · ACS Nano
79. Brown Tumour in Chronic Kidney Disease: Revisiting an Old Disease with a New Perspective
    Djoko Santoso, Mochammad Thaha, Maulana Antiyan Empitu, Ika Nindya Kadariswantiningsih, Satriyo Dwi Suryantoro, Mutiara Rizki Haryati, Decsa Medika Hertanto, Dana Pramudya, Siprianus Ugroseno Yudho Bintoro, Nasronudin Nasronudin et al. · 2023 · Cancers
80. Exploration of a Nitromethane-Carbonylation Strategy during Route Design of an Atropisomeric KRASG12C Inhibitor
    James J. Douglas, Matthew R. Tatton, Daniël de Bruin, David Buttar, Calum Cook, Kuangchu Dai, Catalina Ferrer, Kevin W. Leslie, James Morrison, Rachel H. Munday et al. · 2021 · The Journal of Organic Chemistry
81. PTEN deletion drives acute myeloid leukemia resistance to MEK inhibitors
    Amanda M. Smith, Christine R. Zhang, Alexandre S. Cristino, John P. Grady, J. Lynn Fink, Andrew S. Moore · 2019 · Oncotarget
82. Effect of RAS mutations and related immune characteristics on the prognosis of patients with MSI-H/dMMR colorectal cancer
    Yupeng Jiang, Yuyao Liu, Hong Huang, Tiantian Zhao, Zengyi Zhao, Yawen Gao · 2025 · Cancer Immunology Immunotherapy
83. Targeting KRAS G12D : Advances in Inhibitor Design
    Kaiyin Shi, Amin Li · 2025 · Thoracic Cancer
84. Spatial distribution and activation changes of T cells in pancreatic tumors according to KRAS mutation subtype
    Ji Hye Jeong, Dakyum Shin, Sang‐Yeob Kim, Dong‐Jun Bae, Young Hoon Sung, Eun-Young Koh, Jinju Kim, Chong Jai Kim, Jae Soon Park, Jung Kyoon Choi et al. · 2025 · Cancer Letters
85. Enhanced interpretation of 935 hotspot and non-hotspot RAS variants using evidence-based structural bioinformatics
    Swarnendu Tripathi, Nikita R. Dsouza, Angela Mathison, Elise N. Leverence, Raul A. Urrutia, Michael T. Zimmermann · 2021 · Computational and Structural Biotechnology Journal
86. A First-Class Degrader Candidate Targeting Both KRAS G12D and G12V Mediated by CANDDY Technology Independent of Ubiquitination
    Etsuko Miyamoto‐Sato, Satoshi Imanishi, Lijuan Huang, Shoko Itakura, Yoichi Iwasaki, Masamichi Ishizaka · 2023 · Molecules
87. Role of KRAS in regulating normal human airway basal cell differentiation
    Fumihiro Ogawa, Matthew S. Walters, Afrah Shafquat, Sarah L. O’Beirne, Robert J. Kaner, Jason G. Mezey, Haijun Zhang, Philip L. Leopold, Ronald G. Crystal · 2019 · Respiratory Research
88. Growth Signaling Networks Orchestrate Cancer Metabolic Networks
    Brendan D. Manning, Christian C. Dibble · 2024 · Cold Spring Harbor Perspectives in Medicine
89. Comprehensive structure-function analysis reveals gain- and loss-of-function mechanisms impacting oncogenic KRAS activity
    Jason J. Kwon, Julien Dilly, Shengwu Liu, Eejung Kim, Yuemin Bian, Srisathiyanarayanan Dharmaiah, Timothy H. Tran, Kevin S. Kapner, Seav Huong Ly, Xiaoping Yang et al. · 2024 · bioRxiv (Cold Spring Harbor Laboratory)
90. Lead Identification of Novel Naphthyridine Derivatives as Potent SOS1 Inhibitors
    Dongsheng Li, Qing Xie, Maozhi Yang, Yalei Cai, Kang Sun, Shujuan Jiang, Songda Yu, Lei Liu, Yixiang Zhang, Bing Yu et al. · 2024 · ACS Medicinal Chemistry Letters
91. Targeting KRAS in gynecological malignancies
    Yuanyuan Peng, Qing fan Yang · 2024 · The FASEB Journal
92. Origin, development and therapy of colorectal cancer from the perspective of a biologist and an oncologist
    Jiří Švec, Jakub Onhajzer, Vladimír Kořínek · 2024 · Critical Reviews in Oncology/Hematology
93. Unraveling and targeting RAS-driven metabolic signaling for therapeutic gain
    Jonathan M. DeLiberty, Ryan N. Robb, Claire E. Gates, Kirsten L. Bryant · 2022 · Advances in cancer research
94. Prognostic and Immunotherapeutic Roles of KRAS in Pan-Cancer
    Kaixin Yang, Chengyun Li, Yang Liu, Xueyan Gu, Longchang Jiang, Lei Shi · 2022 · Cells
95. Virtual Screening Based on Machine Learning Explores Mangrove Natural Products as KRASG12C Inhibitors
    Lianxiang Luo, Tongyu Zheng, Qu Wang, Yingling Liao, Xiaoqi Zheng, Ai Zhong, Zunnan Huang, Hui Luo · 2022 · Pharmaceuticals
96. Expression of Immuno-Oncologic Biomarkers Is Enriched in Colorectal Cancers and Other Solid Tumors Harboring the A59T Variant of KRAS
    Emil Lou, Joanne Xiu, Yasmine Baca, Andy Nelson, Benjamin Adam Weinberg, Muhammad Shaalan Beg, Mohamed E. Salem, Heinz‐Josef Lenz, Philip Philip, Wafik S. El‐Deiry et al. · 2021 · Cells
97. Reference Samples to Compare Next-Generation Sequencing Test Performance for Oncology Therapeutics and Diagnostics
    John D. Pfeifer, Robert D. Loberg, Catherine Lofton–Day, Barbara A. Zehnbauer · 2021 · American Journal of Clinical Pathology
98. TRIM37 Promotes Pancreatic Cancer Progression through Modulation of Cell Growth, Migration, Invasion, and Tumor Immune Microenvironment
    Tuyen Thi, Chun‐Chieh Yeh, Guowei Wu, Chia‐Chen Hsu, Hung‐Chih Chang, Hui‐Chen Chen · 2022 · International Journal of Molecular Sciences
99. The Application of Nanotechnology for Quantification of Circulating Tumour DNA in Liquid Biopsies: A Systematic Review
    Nathan J. W. Wu, Matthew Aquilina, Bin‐Zhi Qian, Remco Loos, Inés González-Garcı́a, Cristina Costa Santini, Katherine E. Dunn · 2022 · IEEE Reviews in Biomedical Engineering
100. Fibroblast-Induced Paradoxical PI3K Pathway Activation in PTEN-Competent Colorectal Cancer: Implications for Therapeutic PI3K/mTOR Inhibition
     Fabiana Conciatori, Erica Salvati, Ludovica Ciuffreda, Senji Shirasawa, Italia Falcone, Francesco Cognetti, Gianluigi Ferretti, Massimo Zeuli, Donatella Del Bufalo, Chiara Bazzichetto et al. · 2022 · Frontiers in Oncology